Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination - International Journal of Infectious Diseases

The immune responses and safety of fractional third-doses of heterologous COVID-19 vaccines after CoronaVac primary series

Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study - The Lancet Infectious Diseases

Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil, Antimicrobial Stewardship & Healthcare Epidemiology

Accelerated waning of COVID-19 vaccine immunity in obesity

Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2–Exposed CoronaVac- Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study in: The American Journal of Tropical

Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study - ScienceDirect

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study - The Lancet Regional Health – Americas

Study compares efficacy of BNT162b2 and CoronaVac as the booster dose for COVID-19 vaccination